Format

Send to

Choose Destination
Support Care Cancer. 2018 Apr;26(4):1019-1028. doi: 10.1007/s00520-017-4013-0. Epub 2017 Dec 14.

Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.

Author information

1
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Ian_Kleckner@URMC.Rochester.edu.
2
Cancer Control Center, Department of Surgery, University of Rochester Medical Center, 265 Crittenden Blvd., Box CU 420658, Rochester, NY, 14642, USA. Ian_Kleckner@URMC.Rochester.edu.
3
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
4
Wichita NCI Community Oncology Research Program (NCORP), Wichita, KS, USA.
5
Greenville NCORP, Greenville, SC, USA.
6
Hawaii NCORP, Honolulu, HI, USA.
7
MD Anderson Cancer Center, Houston, TX, USA.

Abstract

PURPOSE:

Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms.

METHODS:

Cancer patients (N = 355, 56 ± 11 years, 93% female, 79% breast cancer) receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy were randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0-10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise effectiveness.

RESULTS:

Exercise reduced CIPN symptoms of hot/coldness in hands/feet (-0.46 units, p = 0.045) and numbness and tingling (- 0.42 units, p = 0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p = 0.086), male (p = 0.028), or had breast cancer (p = 0.076).

CONCLUSIONS:

Exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy. Clinicians should consider prescribing exercise for these patients.

TRIAL REGISTRATION:

Clinical Trials.gov , # NCT00924651, http://www.clinicaltrials.gov .

KEYWORDS:

CIPN; Exercise; Neuropathy

PMID:
29243164
PMCID:
PMC5823751
[Available on 2019-04-01]
DOI:
10.1007/s00520-017-4013-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center